These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 38849701)

  • 1. Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan.
    Lombardi C; Comberiati P; Ridolo E; Cottini M; Yacoub MR; Casagrande S; Riccò M; Bottazzoli M; Berti A
    Drugs; 2024 Jun; 84(6):661-684. PubMed ID: 38849701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-IL5 therapies for asthma.
    Farne HA; Wilson A; Powell C; Bax L; Milan SJ
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-IL-5 therapies for asthma.
    Farne HA; Wilson A; Milan S; Banchoff E; Yang F; Powell CV
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD010834. PubMed ID: 35838542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B; Xue L; Pavord ID
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The spectrum of therapeutic activity of mepolizumab.
    Cavaliere C; Frati F; Ridolo E; Greco A; de Vincentiis M; Masieri S; Makri E; Incorvaia C
    Expert Rev Clin Immunol; 2019 Sep; 15(9):959-967. PubMed ID: 31424304
    [No Abstract]   [Full Text] [Related]  

  • 6. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
    Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
    Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
    Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mepolizumab: First Global Approval.
    Keating GM
    Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
    Nagase H; Ueki S; Fujieda S
    Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
    Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
    Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of interleukin-5 for the treatment of eosinophilic diseases.
    Corren J
    Discov Med; 2012 Apr; 13(71):305-12. PubMed ID: 22541618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma].
    Zyryanov SK; Avdeev SN; Ivanov DA; Zhuravleva MV; Kniajeskaia NP; Matveev NV; Nenasheva NA; Fomina DS; Frolov MI
    Ter Arkh; 2020 Dec; 92(12):172-179. PubMed ID: 33720591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
    Harish A; Schwartz SA
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):231-247. PubMed ID: 31919743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
    Busse W; Chupp G; Nagase H; Albers FC; Doyle S; Shen Q; Bratton DJ; Gunsoy NB
    J Allergy Clin Immunol; 2019 Jan; 143(1):190-200.e20. PubMed ID: 30205189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
    Emma R; Morjaria JB; Fuochi V; Polosa R; Caruso M
    Ther Adv Respir Dis; 2018; 12():1753466618808490. PubMed ID: 30354852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging biologic therapies targeting eosinophilic disorders.
    Pitlick MM; Li JT; Pongdee T
    World Allergy Organ J; 2022 Aug; 15(8):100676. PubMed ID: 35983569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the risk of infection events in patients with asthma receiving
    Giossi R; Pani A; Schroeder J; Scaglione F
    Heliyon; 2024 Jan; 10(1):e23725. PubMed ID: 38268596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis.
    Manka LA; Guntur VP; Denson JL; Dunn RM; Dollin YT; Strand MJ; Wechsler ME
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):696-701.e1. PubMed ID: 33548468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis.
    Ramonell RP; Iftikhar IH
    Lung; 2020 Feb; 198(1):95-103. PubMed ID: 31894410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.